GSK to acquire IBT portfolio company Nuvalent

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) announced that its portfolio company, Nuvalent, Inc., has agreed to be acquired by GSK plc for $124 per share in cash. This acquisition represents a 40% premium to Nuvalent's last closing price and a 26% premium to its 30-day volume-weighted average share price. As of June 8, Nuvalent constituted 0.44% of IBT's Net Asset Value. This marks IBT's sixth portfolio company acquisition in 2026, with over 15% of the portfolio having been acquired year-to-date, reflecting strong merger and acquisition activity driven by pharmaceutical companies seeking to replenish pipelines.

Disclaimer*

UK 100

Latest directors dealings